比较狄诺塞麦和双膦酸盐在原发性骨质疏松症中的应用

Comparison of the application of denosumab and bisphosphonates in primary osteoporosis

狄诺塞麦是作用于核因子-κB受体活化因子配体的新型抗骨质疏松药物,而双膦酸盐则是已得到广泛应用的抗骨吸收药物。狄诺塞麦和双膦酸盐有不同的作用机制,但都具有降低骨折风险、增加骨密度、降低骨转换标志物水平的作用,且临床应用大体安全。本综述从作用机制、治疗效果、不良反应、在肾功能不全患者中的应用及药物依从性五个方面分别对上述两种药物进行比较。

Denosumab is a relatively new anti-osteoporotic agent which targets receptor activator of nuclear factor-κB ligand. Bisphosphonates,as a traditional anti-absorptive agent,has been widely used in clinical practice. They have heterogeneous mechanisms,but both have the ability to reduce fracture risk,increase bone mineral density,reduce bone turnover markers level and are generally safe. This review compares the mechanism,therapeutic effects,adverse effects,application in patients with renal insufficiency as well as medicine compliance of these two agents.